Table 1.
n | % | |
---|---|---|
Age, years | ||
Median | 56 | |
Range | 27–74 | |
Receptor status | ||
ER+/HER2− | 35 | 78 |
ER+/HER2+ | 7 | 16 |
ER+/HER2 unknown | 1 | 2 |
Triple-negative | 2 | 4 |
Histologic subtype | ||
Invasive ductal | 37 | 82 |
Invasive lobular | 3 | 7 |
Other | 5 | 11 |
Visceral metastases | ||
Lung metastases | 18 | 40 |
Liver metastases | 28 | 62 |
Bone metastases | 33 | 73 |
Prior hormonal therapy | 42 | 93 |
Prior lines of chemotherapy | ||
0 | 1 | 2 |
1 | 4 | 9 |
2 | 16 | 36 |
≥3 | 24 | 53 |
Prior taxane therapy | 36 | 80 |
Prior anthracycline therapy | 32 | 71 |
Prior bevacizumab | 19 | 42 |
ER estrogen receptor, HER2 human epidermal growth factor receptor-2, VEGF vascular endothelial growth factor